Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Apoptosis and cancer drug targeting
William R. Sellers, David E. Fisher
William R. Sellers, David E. Fisher
Published December 15, 1999
Citation Information: J Clin Invest. 1999;104(12):1655-1661. https://doi.org/10.1172/JCI9053.
View: Text | PDF
Perspective

Apoptosis and cancer drug targeting

  • Text
  • PDF
Abstract

Authors

William R. Sellers, David E. Fisher

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
The core apoptotic machinery. The core apoptotic machinery comprises the...
The core apoptotic machinery. The core apoptotic machinery comprises the caspases, members of the Bcl-2 family, and Apaf-1. Caspase 3 and other effector caspases carry out the process of cellular destruction that accompanies apoptotic signals. Effector caspases are cleaved and activated by initiator caspases, such as caspases 8 and 9. Caspase 8 is a target of activation by death signaling pathways. Bcl-2 family members regulate both mitochondrial damage and caspase activation. Certain antiapoptotic proteins can directly inhibit caspase 9 activation by Apaf-1, and in turn are antagonized by proapoptotic Bcl-2 family members such as tBid. The cleavage of Bid to tBid by caspase 8 and the inhibition of caspase 9 by Bcl-2 family members are examples of interconnections between the caspase pathway and the mitochondrial pathway of apoptosis.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts